The news: Eli Lilly is spending up to $7 billion to buy cancer cell therapy biotech Kelonia Therapeutics. The deal includes an upfront payment of $3.25 billion, with additional payout potential.

Kelonia is developing a new kind of genetic CAR-T cell therapy that works inside a patient's body. It is initially targeting blood cancer, with plans to expand into a broader range of cancers and other serious diseases.

Why it matters: Lilly is building a sustainable pipeline beyond its blockbuster GLP-1 drugs.

• Kelonia is Lilly’s second in vivo CAR-T acquisition after purchasing Orna Therapeutics for up to $2.4 billion in February, and its third in vivo deal after acquiring Verve Therapeutics for $1 billion last July.
• Lilly also acquired CrossBridge Bio ($300 million) earlier this month, and Scorpion Therapeutics’ cancer gene-mutation targeting program for up to $2.5 billion in January 2025.
• In the past six months, Lilly bought neuroscience company Centessa Pharmaceuticals ($6.1 billion), immunology biotech Ventyx (up to $1.1 billion), and ophthalmology company Adverum ($107 million).

Lilly is likely looking to reduce its reliance on GLP-1s with market competition expected to intensify soon. Cancer is Lilly’s second-largest therapeutic area, generating $9.4 billion in 2025 sales. But cardiometabolic drugs dominate, accounting for 74% of Lilly’s $65.2 billion sales last year, led by type 2 diabetes drug Mounjaro ($22.9 billion) and obesity drug Zepbound ($13.5 billion).

Implications for pharma companies: Lilly’s diversification follows its pharma peers into the competitive in vivo CAR-T space, where Gilead Sciences, AbbVie, Bristol Myers Squibb, and AstraZeneca have each struck deals valued at more than $1 billion in the past year. That underscores the growing momentum behind these next-generation cancer therapies, where speed to market and the ability to scale will become key differentiators.

Lilly’s push to diversify also put it at the top of pharma Q1 acquisitions, helping to drive a broader market rebound. Analysts expect a continued strong 2026 across pharma M&A that’s likely to surpass 2025’s deal numbers. That will raise biotech valuations and increase competition, especially for late-stage R&D assets.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.